Clinical Trial Update: A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating melphalan flufenamide (melflufen) plus dexamethasone in relapsed/refractory multiple myeloma has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• melphalan flufenamide (melphalan flufenamide)

Snippet

Sponsor: Oncopeptides AB | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-01